JP4589005B2 - ピロロピリダジン化合物および増殖性疾患治療におけるその使用方法 - Google Patents

ピロロピリダジン化合物および増殖性疾患治療におけるその使用方法 Download PDF

Info

Publication number
JP4589005B2
JP4589005B2 JP2003579751A JP2003579751A JP4589005B2 JP 4589005 B2 JP4589005 B2 JP 4589005B2 JP 2003579751 A JP2003579751 A JP 2003579751A JP 2003579751 A JP2003579751 A JP 2003579751A JP 4589005 B2 JP4589005 B2 JP 4589005B2
Authority
JP
Japan
Prior art keywords
formula
compound
alkyl
group
heterocyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003579751A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006504624A (ja
JP2006504624A5 (enExample
Inventor
マーク・イー・サルバティ
ステファニー・エイ・バーボサ
チェン・ジョン
ジョン・ティ・ハント
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2006504624A publication Critical patent/JP2006504624A/ja
Publication of JP2006504624A5 publication Critical patent/JP2006504624A5/ja
Application granted granted Critical
Publication of JP4589005B2 publication Critical patent/JP4589005B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
JP2003579751A 2002-03-28 2003-03-26 ピロロピリダジン化合物および増殖性疾患治療におけるその使用方法 Expired - Fee Related JP4589005B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36824902P 2002-03-28 2002-03-28
US40211802P 2002-08-08 2002-08-08
PCT/US2003/009550 WO2003082208A2 (en) 2002-03-28 2003-03-26 Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders

Publications (3)

Publication Number Publication Date
JP2006504624A JP2006504624A (ja) 2006-02-09
JP2006504624A5 JP2006504624A5 (enExample) 2006-04-20
JP4589005B2 true JP4589005B2 (ja) 2010-12-01

Family

ID=28678223

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003579751A Expired - Fee Related JP4589005B2 (ja) 2002-03-28 2003-03-26 ピロロピリダジン化合物および増殖性疾患治療におけるその使用方法

Country Status (12)

Country Link
US (2) US6900208B2 (enExample)
EP (1) EP1578351B1 (enExample)
JP (1) JP4589005B2 (enExample)
AR (1) AR039189A1 (enExample)
AT (1) ATE490964T1 (enExample)
AU (1) AU2003223380A1 (enExample)
CL (1) CL2008003391A1 (enExample)
DE (1) DE60335293D1 (enExample)
PE (1) PE20040168A1 (enExample)
PL (1) PL374759A1 (enExample)
TW (1) TW200403245A (enExample)
WO (1) WO2003082208A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0977563B1 (en) * 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
WO2004018478A2 (en) * 2002-08-23 2004-03-04 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
RU2328499C2 (ru) * 2003-01-09 2008-07-10 Астеллас Фарма Инк. Производные пирролопиридазина, фармацевтическая композиция, способ профилактики или лечения заболеваний, применение в качестве ингибитора фосфодиэстеразы iv, и/или продуцирования tnf
US7030112B2 (en) * 2003-03-25 2006-04-18 Bristol-Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) * 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7432373B2 (en) * 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2006004191A1 (en) * 2004-07-05 2006-01-12 Astellas Pharma Inc. Pyrrolopyridazine derivatives which inhibit pde iv and tnf alfa
WO2007035428A1 (en) * 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
EP1953147A1 (en) * 2005-11-21 2008-08-06 Japan Tobacco, Inc. Heterocyclic compound and medicinal application thereof
US8513276B2 (en) 2006-12-22 2013-08-20 Astex Therapeutics Limited Imidazo[1,2-a]pyridine compounds for use in treating cancer
HRP20150642T1 (hr) * 2006-12-22 2015-08-14 Astex Therapeutics Limited BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
AU2009226024B2 (en) 2008-03-20 2012-07-12 Amgen Inc. Aurora kinase modulators and method of use
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
WO2010019473A1 (en) 2008-08-14 2010-02-18 Amgen Inc. Aurora kinase modulators and methods of use
WO2010045095A1 (en) * 2008-10-14 2010-04-22 Ning Xi Compounds and methods of use
WO2010111063A1 (en) * 2009-03-21 2010-09-30 Ning Xi Amino ester derivatives, salts thereof and methods of use
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
NZ807894A (en) 2009-04-29 2025-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
AR077428A1 (es) * 2009-07-29 2011-08-24 Sanofi Aventis (aza) indolizinacarboxamidas ciclicas su preparacion y su uso como agentes farmaceuticos
JP2013501003A (ja) * 2009-07-31 2013-01-10 バイオクライスト ファーマシューティカルズ， インコーポレイテッド ヤヌスキナーゼ阻害剤としてのピロロ［１，２−ｂ］ピリダジン誘導体
JP6386527B2 (ja) * 2013-03-11 2018-09-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ カリウムイオンチャネル阻害剤としてのピロロピリダジン
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
EP3692144A1 (en) 2017-10-05 2020-08-12 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of dux4
JP7093410B2 (ja) * 2017-11-17 2022-06-29 アカデミア シニカ ビス（ヒドロキシメチル）ピロロフタラジン混成物、調製方法及びその用途
WO2020014068A1 (en) 2018-07-09 2020-01-16 Boehringer Ingelheim Animal Health USA Inc. Anthelminthic heterocyclic compounds
TWI842978B (zh) 2018-07-13 2024-05-21 美商基利科學股份有限公司 衍生物
CA3133100A1 (en) 2019-03-19 2020-09-24 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic aza-benzothiophene and aza-benzofuran compounds
AU2021278889A1 (en) 2020-05-29 2023-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anthelmintic heterocyclic compounds
UY39995A (es) 2021-11-01 2023-05-15 Boehringer Ingelheim Vetmedica GmbH Compuestos de pirrolopiridazina como antihelmínticos

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472389B1 (en) * 1998-05-21 2002-10-29 Shionogi & Co., Ltd. Pyrrolo[1,2-b] pyridazine derivatives having sPLA2 inhibitory effect
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
WO2000012074A2 (en) 1998-08-28 2000-03-09 Scios Inc. Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
KR100666514B1 (ko) 1999-05-21 2007-02-28 브리스톨-마이어즈 스퀴브 컴페니 키나제의 피롤로트리아진 저해제
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
JPWO2002000621A1 (ja) * 2000-06-29 2004-04-22 塩野義製薬株式会社 Ｘ型ｓＰＬＡ２阻害作用を有する化合物
NZ525334A (en) 2000-11-17 2005-07-29 Bristol Myers Squibb Co Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6670357B2 (en) 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors

Also Published As

Publication number Publication date
CL2008003391A1 (es) 2009-03-06
EP1578351A4 (en) 2006-06-14
US20040063712A1 (en) 2004-04-01
US20050159420A1 (en) 2005-07-21
AU2003223380A1 (en) 2003-10-13
AU2003223380A8 (en) 2003-10-13
EP1578351B1 (en) 2010-12-08
WO2003082208A3 (en) 2006-03-02
JP2006504624A (ja) 2006-02-09
PE20040168A1 (es) 2004-03-27
DE60335293D1 (de) 2011-01-20
US6900208B2 (en) 2005-05-31
EP1578351A2 (en) 2005-09-28
AR039189A1 (es) 2005-02-09
WO2003082208A8 (en) 2005-03-24
PL374759A1 (en) 2005-10-31
WO2003082208A2 (en) 2003-10-09
TW200403245A (en) 2004-03-01
ATE490964T1 (de) 2010-12-15

Similar Documents

Publication Publication Date Title
JP4589005B2 (ja) ピロロピリダジン化合物および増殖性疾患治療におけるその使用方法
US7531539B2 (en) Pyrrolotriazine kinase inhibitors
US7030112B2 (en) Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
KR101392678B1 (ko) 피롤로트리아진 키나제 억제제
JP6745856B2 (ja) Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体
KR101686685B1 (ko) 피라졸로피리미딘 ｊａｋ 억제제 화합물 및 방법
KR101825754B1 (ko) 피라졸로피리미딘 ｊａｋ 억제제 화합물 및 방법
CN105121407B (zh) 用于治疗癌症的苯甲酸衍生物mdm2抑制剂
US20070060589A1 (en) Inhibitors of protein arginine methyl transferases
HUE031166T2 (hu) Kináz inhibitorként aktív szubsztituált indazolok
RS60468B1 (sr) Nova jedinjenja
RS20050944A (sr) Derivati pirazolo- hinazolina,postupci za njihovo dobijanje i njihova upotreba kao inhibitora kinaze
JP7222590B2 (ja) ３－アザビシクロ［３，１，１］ヘプタン誘導体及びこれを含む薬学的組成物
JP2011525183A (ja) キナーゼ阻害剤として有用なイミダゾピリジンおよびイミダゾピラジン化合物
JP5073655B2 (ja) キナーゼ阻害物質として有用なピロロトリアジンおよびそれを用いるキナーゼ関連疾患の治療方法
JP2011525184A (ja) キナーゼ阻害剤として有用なトリアゾロピリジン化合物
JP6322275B2 (ja) ヤヌスキナーゼ阻害剤としてのｎ−（２−シアノヘテロシクリル）ピラゾロピリドン
JP2016514709A (ja) ヤヌスキナーゼ阻害剤としてのジェミナル置換シアノエチルピラゾロピリドン
JP7034942B2 (ja) ピラゾール誘導体、その組成物及び治療的使用
KR100846370B1 (ko) 파네실 트랜스퍼라아제 저해성 1,2-어닐링된 퀴놀린에난티오머
ES2355718T3 (es) Compuestos de pirrolopiridazina y procedimientos de uso de los mismos para el tratamiento de trastornos proliferativos.
HK1196355A (en) Compounds useful as inhibitors of choline kinase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060301

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091201

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20091201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100405

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100506

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100804

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100831

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100909

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130917

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees